With respect to the forward-looking statements contained in this news release , we have made numerous assumptions regarding , among other things : our ability to complete a rights offering ; the adequacy of the OmigardTM Phase III trial design to generate data that are deemed sufficient by regulatory authorities to support potential regulatory filings , including an NDA , for OmigardTM ; Cutanea 's ability to manage , fund and advance omiganan for dermatological applications into Phase III and submit a NDA ; our ability to manage licensing opportunities ; and future expense levels being within our current expectations .